NXP800

NXP800 activity in ARID1A and ARID1B-deficient endometrial cancer xenografts
(Special AACR, endometrial cancer, 2023)
Results of a phase 1 dose escalation of NXP800 in patients with advanced solid tumors
(ENA 2023)
Inhibition of HSF1 demonstrates therapeutic efficacy in preclinical PDX models of cholangiocarcinoma (AACR 2023)
Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800 (AACR 2023)
NXP800 versus cisplatin in ARID1a-mutated ovarian clear cell carcinoma xenograft models (ESMO Gyne 2023)
HSF1 pathway inhibitor developed as a potential treatment for refractory ovarian cancer
(Journal of Med. Chem. 2023)
NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
(New Drugs on The Horizon, AACR 2022)
Discovery and validation of biomarkers to support clinical development of NXP800
(ENA 2022)